Overview
This study is a prospective cross-sectional study in which surgically non-invasive sampletaking is done only for the purpose of the study. Capillary (fingerstick) whole blood and plasma (i.e., obtained through venous EDTA whole blood collection and processing) are collected by a healthcare professional. The collected samples are tested in a routine testing environment, i.e., healthcare providers at
Description
A trained healthcare provide will collect 50μL of capillary whole blood and 11mL of EDTA venous whole blood (VWB) to be tested with the iStatis Syphilis Ab Test on site according to the 'Test Procedure' described in the Instructions for Use (IFU) supplied with the reagents. Same procedure must be followed using the extracted plasma sample to test 30μL of the plasma sample extracted and obtained through processing of the VWB on the iStatis Syphilis Ab Test. An aliquot of the plasma sample will be transferred to the central laboratory to establish the reference test result using an enzyme immunoassay (EIA) (Abbott Architect Syphilis Tp EDA). In case of positive results in the EIA reference test of (Abbott Architect Syphilis Tp EDA), the sample will be sent for BD Macro-Vue Particle Agglutination (RPR) and Serodia Particle Agglutination (TPPA) testing.
Eligibility
Inclusion Criteria:
- Participants/subjects (males, females, and pregnant women) getting tested for syphilis
for one or more of the following reasons:
- at risk for syphilis ohaving signs and symptoms indicative for syphilis oRoutine testing
- Participants/subjects of 18 years or older and, who are able to give/sign the informed
consent.
Exclusion Criteria:
- Participant younger than 18 years old
- Participants unable to provide written informed consent
- Participants currently undergoing treatment